RBC Capital rated the company’s stock at “outperform.” Boston Scientific stock has a 52-week high of $18.40 and a 52-week low of $11.10, according to the report.
More articles on gastroenterology:
7 things for gastroenterologists to know for today – April 17, 2015
Alternative payment models in GI: What’s on the horizon?
3 GI physicians making headlines – April 17, 2015
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
